Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

Hepatology International

Volumn 3, Issue 2, 2009, Pages 403-410

  Kobashi, Haruhiko ^a   Fujioka, Shin Ichi ^b   Kawaguchi, Mitsuhiko ^b   Kumada, Hiromitsu ^c   Yokosuka, Osamu ^d   Hayashi, Norio ^e   Suzuki, Kazuyuki ^f   Okanoue, Takeshi ^g   Sata, Michio ^h   Tsubouchi, Hirohito ⁱ   Sato, Chifumi ^j   Kiyosawa, Kendo ^k   Tanikawa, Kyuichi ^l   Seriu, Taku ^m   Ishikawa, Hiroki ^m   Takaki, Akinobu ^a   Iwasaki, Yoshiaki ^a   Osawa, Toshiya ^b   Takaki, Toshiyuki ^b   Sakaguchi, Kosaku ^a   Shiratori, Yasushi ^a   Yamamoto, Kazuhide ^a   Tenney, Daniel J ^m   Omata, Masao ⁿ   more..

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f IWATE MEDICAL UNIVERSITY   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KAGOSHIMA UNIVERSITY   (Japan)

^j TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^k SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KURUME UNIVERSITY   (Japan)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Chronic hepatitis B; Drug resistance; Entecavir; HBV; Nucleoside naive

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ENTECAVIR; GLYCINE; GLYCYRRHIZIC ACID; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LEUCINE; METHIONINE; NUCLEOSIDE ANALOG; SERINE; URSODEOXYCHOLIC ACID; VALINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; DISEASE COURSE; DNA SEQUENCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; REBOUND; SCREENING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 65049086668     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9108-8     Document Type: Article

References (28)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107. doi: 10.1046/j.1365-2893.2003.00487.x
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956. doi:10.1002/ 1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. doi: 10.1001/jama.295.1.65
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. doi: 10.1053/j.gastro.2005.11.016
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68. doi: 10.1056/NEJM199807093390201
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531. doi: 10.1056/NEJMoa033364
7. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572. doi: 10.1002/ hep.510300221
8. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. doi: 10.1053/j.gastro.2003.09.033
9. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455. doi: 10.1172/JCI11100
10. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444. doi: 10.1053/ j.gastro.2007.08.025
11. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. doi: 10.1056/NEJMoa051287
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539. doi: 10.1002/hep.21513
13. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006;4:936-962. doi: 10.1016/j.cgh.2006.05.016
14. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-1665. doi: 10.1002/hep.21422
15. Colonno R, Rose R, Pokornowski K, Baldick C, Eggers B, Yu D, et al. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. J Hepatol 2007;46:S294. doi: 10.1016/ S0168-8278(07)62379-4 (abstract)
16. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007;39:149-152. doi: 10.1016/j.jcv.2007.03.004
17. Kessler HH, Pierer K, Dragon E, Lackner H, Santner B, Stünzner D, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol 1998;9:37-43. doi: 10.1016/ S0928-0197(97)10008-3
18. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996;6:112-119. doi: 10.1016/ S0928-4346(96)00325-8
19. Punia P, Cane P, Teo CG, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004;40:986-992. doi: 10.1016/ S0168-8278(04)00062-5
20. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696. doi: 10.1086/368083
21. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297. doi: 10.1016/S0016-5085(03)00939-9
22. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751. doi: 10.1053/ j.gastro.2006.09.020
23. Hepsera (Adefovir dipivoxil) current US package insert. CA: Gikead Sciences. p. 3
24. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507. doi: 10.1128/ AAC.48.9.3498-3507.2004
25. Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, et al. Hepatitis B virus quasi-species susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008;48:895-902. doi: 10.1016/j.jhep.2007.12.024
26. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-911. doi: 10.1128/AAC.00833-06
27. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46:531-538. doi: 10.1016/j.jhep.2006.11.016
28. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897. doi: 10.1016/j.cgh.2007.05.004